The Medipattern Corporation
TSX VENTURE : MKI

The Medipattern Corporation

December 20, 2006 06:30 ET

MammoSolutions Signs Reseller Agreement With Medipattern

TORONTO, ONTARIO--(CCNMatthews - Dec. 20, 2006) -

Attention: Business/Financial Editors

The Medipattern Corporation (TSX VENTURE:MKI), an award-winning developer of computer-aided diagnosis (CAD) software applications for medical imaging, and Houston-based MammoSolutions, Inc., a reseller of systems focused on breast cancer detection and treatment, today announced that MammoSolutions will distribute Medipattern's B-CADTM ultrasound CAD product in the southwestern United States.

B-CAD is the only commercially available breast ultrasound CAD product in the industry, and naturally has an advantageous position in the breast imaging software market. This agreement arises out of Medipattern's newly focused sales strategy, and not only reflects Medipattern's significant industry profile but forms an integral component of Medipattern's objective to create its own end-user sales channel.

"We are very excited to have the opportunity to be a reseller of Medipattern's B-CAD. We have represented mammography CAD solutions since they were first available in the US market, during which time, we have seen the value that CAD provides in identifying subtle cancers," said Cindy Ulmet, President of MammoSolutions.

"B-CAD furthers this capability by automatically listing the key features to characterize each lesion, generating an American College of Radiologists' BI-RADS® score for breast imaging analysis, and then organizes all of the information for the radiologist in a natural language report that can be printed or electronically stored," stated Jeff Collins, CEO of Medipattern. "Medipattern's alignment with MammoSolutions marks the beginning of our strategic reseller program to penetrate the end-user market, and represents the first of many such relationships planned by Medipattern. Targeted resellers provide a powerful conduit for specialized breast cancer facilities to understand and incorporate new technologies while remaining focused on their daily challenge to detect and diagnose breast cancer earlier. B-CAD offers radiologists the ability to improve accuracy, increase diagnostic confidence, and improve workflow in documenting and reporting their findings. These process enhancements may, in turn, shorten the treatment cycle and improve survival rates for the millions of women who have ultrasound procedures every year."

MammoSolutions was founded in 2002 to provide access to various breast-cancer-focused solutions for the expanding screening and diagnostic end user market. Breast cancer clinics benefit from MammoSolutions' expertise in making available to them, the latest innovations and solutions in detecting and diagnosing breast cancer.

Upcoming Events:

Medipattern will be at Women's Health 2007 January 22 to January 24, 2007 in San Antonio Texas.

Medipattern will be at the European Congress of Radiology, March 9 to March 13, 2007, and plans to demonstrate its software at the Kodak, Confirma, Sectra, and Cedara booths as well as its own booth.

About The Medipattern Corporation

Medipattern develops computer-aided diagnosis (CAD) software applications for medical imaging. These applications enhance workflow while improving interpretive and diagnostic confidence. The Company's initial clinical applications are B-CAD™ for breast ultrasound and the award-winning B-CAD MRI™. The B-CAD products use pattern recognition technology to assist radiologists in their efforts to classify and characterize lesions in images of the breast. Please visit the company's website at: www.medipattern.com.

B-CAD™ and B-CAD MRI™ are trademarks of The Medipattern Corporation.

Medipattern® is a registered mark of The Medipattern Corporation.

Forward-looking statements

This document contains forward-looking statements relating to Medipattern's performance, operations, or business environment. These statements are based on what we believe are reasonable assumptions given currently available information and our understanding of Medipattern's current activities. We have tried, whenever possible, to identify these forward-looking statements using words such as "anticipates,'' "believes,'' "estimates,'' "expects,'' "plans,'' "intends,'' "potential'', and similar expressions. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict or control. A number of factors could cause actual outcomes and results to differ materially from those expressed in forward-looking statements. These factors include but are not limited to those set forth in the Company's corporate filings, (posted at www.sedar.com). In addition, these forward-looking statements relate to the date on which they are made. The Company disclaims any intention or obligation to update or revise any forward-looking statements for any reason. Readers should not rely on forward-looking statements.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release and has neither approved nor disapproved of the contents of this release.

Contact Information